Vivo Bio Tech Ltd (VIVOBIOT) is currently trading at 29.40 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Vivo Bio Tech Limited is a full-service Contract Research Organization (CRO) providing drug development and discovery services globally. It specializes in preclinical testing, offering both in-vitro and in-vivo studies. The company has established itself as India's largest breeder and distributor of rodent models, providing SPF lab animals for preclinical studies. Vivo Bio Tech partners with global entities like Cyagen Biosciences and Taconic to enhance genomic technologies and animal model supplies. In 2021-22, the company expanded its scope beyond animal breeding, transforming into a comprehensive CRO focusing on various analytical and pharmacological studies. Vivo Bio Tech is committed to quality and standards, as evidenced by its ISO 9001:2015 certification and compliance with OECD guidelines for preclinical studies.

Over the past 52 weeks, Vivo Bio Tech Ltd has traded between a low of ₹25.21 and a high of ₹56.47. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Vivo Bio Tech Ltd has a market capitalization of approximately 64.24. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Vivo Bio Tech Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 15.73 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

You can buy shares of Vivo Bio Tech Ltd (VIVOBIOT) through any SEBI-registered stockbroker in India. A demat and trading account are required to place buy or sell orders on stock exchanges such as NSE or BSE. Shares are credited to the demat account as per the exchange settlement cycle.

Based on its market capitalization of 64.24 Cr, Vivo Bio Tech Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Vivo Bio Tech Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Vivo Bio Tech Ltd is 15.73. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Vivo Bio Tech Ltd currently does not pay dividends. Companies that do not pay dividends often reinvest profits to support business growth or strengthen operations.

Key risks associated with Vivo Bio Tech Ltd include sector-specific challenges in the Pharmaceuticals industry, regulatory changes, competitive pressures, company-level financial performance, overall market volatility, and broader macroeconomic factors that can impact stock prices.